SnET2: PDTI began a Phase I/II dose escalation study of SnET2.

PDT Inc. (PDTI), Santa Barbara, Calif. Product: SnET2, photodynamic therapy Indication: Age-related macular degeneration Status: PDTI began a Phase I/II dose escalation study of SnET2. The therapy is ...